About BBOT
BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. Initially formed as a subsidiary of BridgeBio Pharma, Inc., BBOT aims to improve outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. The company went public on Nasdaq (ticker: BBOT) in August 2025 via a SPAC merger with Helix Acquisition Corp. II.
Company details
Funding
Total raised
$461M
Last stage
Public
Investors
Founders
Idan Elmelech
CFO of BBOT, responsible for financial strategy and operations of the clinical-stage biotech.
Eli Wallace
PhD; led BBOT as CEO from its 2024 spinout from BridgeBio Pharma; previously Chief Scientific Officer at Peloton Therapeutics; stepped down as CEO in April 2026.
Pedro J. Beltran
PhD; co-founded and served as Chief Scientific Officer at BBOT; appointed CEO in April 2026 following Eli Wallace's departure.
LinkedInNeil Kumar
PhD; Founder & CEO of BridgeBio Pharma; instrumental in spinning out BBOT in 2024; appointed Executive Chairman of BBOT in April 2026.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.